September S&P 500 futures (ESU23) are up +0.10%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.13% this morning after three major U.S. benchmark indices ended the regular session higher as...
Dr. Reddy's (RDY) reports better-than-expected fourth-quarter results where both earnings and revenues beat estimates.
Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%....
Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the...
Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.
Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.
Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address...
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address...
Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the...